Cinnamon bark is associated
with many health benefits. Not only is this spicy-sweet herb a potent
antioxidant, but it also demonstrates promise as a holistic treatment option
for medical conditions including diabetes, high cholesterol, intestinal
problems and poor appetite.
Although
cinnamon is very safe when used in food and somewhat safe when taken as a
supplement, there are some cinnamon bark contraindications. Some people should
not take cinnamon. Avoid all supplements containing cinnamon bark if you fall
into any of these high-risk categories.
Pregnant Women
No
studies have evaluated cinnamon's safety for pregnant women, and there is not
enough evidence to suggest that it is beneficial as a supplement for expectant
mothers. Pregnancy is considered to be a cinnamon bark contraindication. In
theory, it may trigger contractions in the uterus, leading to an increased risk
of miscarriage and preterm labor. It is not known if cinnamon contributes to
birth defects of any kind.
People with Liver Disease
Cinnamon
bark is contraindicated for people with liver diseases such as fibrosis, hepatitis, and
cirrhosis. Compounds in cinnamon bark are metabolized by the liver and may
worsen these conditions. The body may be unable to filter the mildly toxic
by-products involved in metabolizing cinnamon, and this could lead to serious
consequences. Avoid cinnamon bark supplements in you have a history of any
liver condition.
People Taking Hepatotoxic Drugs
Certain
drugs can increase the possibility of liver problems in people taking cinnamon
supplements. Experts advise patients to avoid taking cinnamon supplements,
especially in large doses, if they are using any medication that is
hepatotoxic, or potentially harmful to the liver. Hepatotoxic drugs include
Tylenol, Cordarone, Tegretol, Rheumatrex, Aldomet, Diflucan, Sporanox,
Erythrocin, Dilantin, and statin drugs such as Mevacor, Pravachol, and Zocor. If
you are uncertain about your potential risks, check with your health care
provider to see if you are using a hepatotoxic drug.
No comments:
Post a Comment